The promise of decentralised models and diversity in clinical trials
ICON invited senior executives from Amgen, Sanofi, Eli Lilly and Janssen Research & Development LLC to discuss how decentralised and hybrid clinical trial models can provide increased resilience and how their respective organisations are currently or likely to address diversity and inclusion in clinical trials into the future.
Read our summary report for insight into how organisations responded rapidly to the developments in 2020 and how this is paving the way for continuous improvements into the future.
Practical considerations in transitioning to hybrid or decentralised clinical trials
Everyone is talking about decentralised clinical trials. But how can we leverage what we learnt during 2020 and move forward in a more systematic way to deploy this approach with maximum efficiency and optimum results?